U.S. markets closed

Dyadic International, Inc. (DYAI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.01-0.08 (-1.57%)
At close: 4:00PM EDT

5.01 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Pennant (Bearish)

Pennant (Bearish)

Previous Close5.09
Bid4.90 x 1300
Ask5.37 x 1100
Day's Range4.86 - 5.14
52 Week Range4.56 - 10.98
Avg. Volume624,759
Market Cap138.047M
Beta (5Y Monthly)0.06
PE Ratio (TTM)N/A
EPS (TTM)-0.34
Earnings DateMay 12, 2021 - May 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • What Kind Of Shareholders Hold The Majority In Dyadic International, Inc.'s (NASDAQ:DYAI) Shares?
    Simply Wall St.

    What Kind Of Shareholders Hold The Majority In Dyadic International, Inc.'s (NASDAQ:DYAI) Shares?

    A look at the shareholders of Dyadic International, Inc. ( NASDAQ:DYAI ) can tell us which group is most powerful...

  • DYAI: Headed to the Clinic
    Zacks Small Cap Research

    DYAI: Headed to the Clinic

    By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT 2020 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) released 2020 operational and financial results on March 30, 2021 and concurrently filed its Form 10-K with the SEC. A Phase I trial is planned in 2H:21 that will evaluate the safety of a C1-produced vaccine in human subjects. Following the


    Dyadic Reports 2020 Year End Results and Recent Company Progress

    2 million at year-end 2020JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs and other commercial products at flexible commercial scales, today announced its financial results for 2020 and recent business highlights.